Back to catalogue
NIOX
Niox Group PLC
430/1000 Overall fit
AI beneficiary 35% 25
Operating leverage 25% 65
Valuation 25% 30
Downside protection 15% 72
First-pass take
Market-leading FeNO diagnostic device company with 17% revenue growth, 34% EBITDA margins, strong net cash (£19.9m), and 90%+ recurring consumables revenue. However, zero AI/ML exposure or enterprise AI spending tailwinds limits strategic fit. No valuation data in filing.
Flags
no-ai-exposureno-valuation-datarecurring-revenue-modelnet-cashmedical-deviceearly-stage-adoption-risk